Progress in Cardiovascular Pharmacology

Dear Colleagues,

Cardiovascular diseases (CVDs) still represent the main cause of death worldwide, with increasingly higher rates being reported in the literature. More specifically, the influence of CVD on quality of life is even more dramatic, as the loss in quality-adjusted life years (QALYs) negatively impacts economics as well due to direct and indirect costs related to reduced skills in performing daily activities.

Recently, innovations in cardiologic treatments have represented the cornerstone for reversing the impact of CVD on the overall prognosis of patients, with noninvasive approaches providing interesting insights on counteracting disease progression and the worsening of alterations in cardiac and vascular structures and function.

The most intriguing research efforts are now concentrating on a molecular approach to CVD, based on techniques regulating gene transcription and—in the near future—influencing protein transduction and gene editing.

The final goal of pharmacological innovations is to provide therapies tailored to a single patient’s clinical characteristics by identifying and modifying genetic abnormalities, restoring the original function.

The scientific community looks forwards to hearing and learning these new approaches to diseases, particularly CVD.

The aim of this Special Issue is to provide the most recent advances in pharmacological approaches to CVD to define their future impact on patient prognosis and the reversal of clinical outcomes.

Prof. Dr. Pietro Scicchitano
Dr. Francesco Massari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.